Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2014)
16 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 18, 2014
Slide 1: 2014 Annual General Meeting: CEO Address
For personal use only 2014 Annual General Meeting: CEO Address Dr Ross Macdonald, CEO, Cynata Therapeutics Limited November, 2014 Copyright and Confidential
Slide 2: Important information
Important information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 3: Cynata Therapeutics Ltd Key Facts
Cynata Therapeutics Ltd Key Facts For personal use only ASX: Resumed trading Nov 2013 as CYP (prev ECQ) Capital raised in Nov 2013: $5m Market Cap (17 Nov 14): $19.4m Shares on Issue*: 55.0m Options (Dec 14, $0.2): 11.11m Cash (30 Sep 14): $4.7m (18 months runway) Number of shareholders: ~1150 Busin
Slide 4: Cynata's Cymerus: Outstanding Pedigree
Cynata’s Cymerus : Outstanding Pedigree TM For personal use only • Inventors include Dr James Thomson • In 1998 derived the first human embryonic stem cell line • 2007 derived human induced pluripotent stem cells • Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field •
Slide 5: Why are Mesenchymal Stem Cells (MSCs) Important?
Why are Mesenchymal Stem Cells (MSCs) Important? For personal use only MSC therapies are here and now: Spinal cord injury Neurodegenerative diseases (eg MS) Eye diseases (eg AMD) Chronic wounds Stroke Myocardial infarction (heart attack) Graft-versus-host disease (GvHD) Bone fracture; cartilage repa
Slide 6: Headlines……
For personal use only Headlines……
Slide 7: Stroke: A Case Study
Stroke: A Case Study For personal use only • Devastating affliction that strikes young and old alike • I.V. MSCs could be a safe therapy for promoting neurovascular repair, consequently supporting better functional recovery: trials underway • Strokes cost the US economy $36.5b p.a. with 795,000 pati
Slide 8: Roadblock for MSC Medicines: Manufacture
Roadblock for MSC Medicines: Manufacture For personal use only
Slide 9: Current Manufacture of Stem Cell (MSC) Medicines
Current Manufacture of Stem Cell (MSC) Medicines For personal use only • Extract stem cells from human donor (eg bone marrow) • MSCs represent a rare fraction of the cells in these tissues: a typical BM donation contains <20,000 MSCs • BUT: A typical clinical dose is >100 million MSCs • This means t
Slide 10: Multiple Donors – Multiple Problems
Multiple Donors – Multiple Problems For personal use only • Recruitment and qualification of donors is costly, time consuming and is associated with logistical challenges • May involve risk/discomfort to donor – especially with bone marrow or adipose tissue • Intra- and inter- donor variability is l
Slide 11: This issue is attracting increasing attention
This issue is attracting increasing attention For personal use only “[lower] number of MSC expansion passages could be correlated to both better response and better survival” “the most egregious divergence between [commercial and academic MSC products] is the scale of product expansion. The industri
Slide 12: Commercial Manufacture of MSC Therapies
Commercial Manufacture of MSC Therapies For personal use only THE SOLUTION: Cynata’s Cymerus™ technology facilitates commercial-scale manufacture of a consistent, reproducible product: …”better, cheaper, faster”
Slide 13: Path to Revenue
Path to Revenue For personal use only • Following two paths to monetise the Cymerus™ technology – Make our own stem cell medicines (GvHD and others progressing): confirm manufacturing process and efficacy; – Capital efficient license-driven strategy: partner with pharmaceutical companies and large b
Slide 14: Cynata Therapeutics: The Past Months
Cynata Therapeutics: The Past 12 Months For personal use only • Building a solid foundation for the future: – Timetable and budget consistent with October 2013 prospectus and market updates – Recruited VP, Product Development (ex MSB) – Product manufacturing and process development well advanced (Wa
Slide 15: Cynata: The Year Ahead
Cynata: The Year Ahead For personal use only • Important Development Milestones and Value Catalysts: – Complete master cell bank (MCB) – Complete manufacturing scale-up: manufacture CymerusTM GMP MSC’s – Formal interaction with regulatory agencies (eg EMA, FDA) – Data from pre-clinical program and P
Slide 16: Thank you for your attention
For personal use only Thank you for your attention
Cynata Therapeutics — Shareholder Meeting (November 2014) on 6ix